You are here: Industry Insights > Bioasis

News List

Bioasis Announces the Appointment of Dave Jenkins as CFO firstwordpharma
July 02, 2021
BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the "Company" or "Bioasis") today announced the appointment of Dave Jenkins as Chief Financial Officer.
Bioasis Technologies and Oxyrane UK enter into a Research Collaboration firstwordpharma
July 01, 2021
Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF) ("Bioasis") and Oxyrane UK Ltd. ("Oxyrane") are pleased to announce the initiation of a research collaboration.
Bioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind Partners firstwordpharma
June 30, 2021
Bioasis Technologies Inc. announced today that it has closed on initial funding under the previously announced convertible security funding agreement (the "Agreement") with Lind Global Macro Fund, LP, an entity managed by The Lind Partners, LLC.
Bioasis Completes Bridge Financing Transaction firstwordpharma
December 24, 2019
Pursuant to the Bridge Financing, Bioasis issued a total of approximately CAD$696,000 unsecured debentures (the "Debentures") to a group of arm's length investors.
WuXi Biologics, Bioasis in Strategic Dev./Mfg. Alliance contractpharma
May 22, 2018
WuXi Biologics and Bioasis Technologies, Inc. have entered an initial strategic collaboration for the development and manufacture of xB3-001, Bioasis' lead biologic candidate to treat brain cancer.